{"nctId":"NCT00477971","briefTitle":"Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis","startDateStruct":{"date":"2005-10"},"conditions":["Multiple Myeloma and Plasma Cell Neoplasm"],"count":89,"armGroups":[{"label":"Arm A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: dexamethasone","Drug: melphalan"]},{"label":"Arm B","type":"EXPERIMENTAL","interventionNames":["Biological: filgrastim","Drug: melphalan","Procedure: autologous hematopoietic stem cell transplantation"]}],"interventions":[{"name":"filgrastim","otherNames":[]},{"name":"dexamethasone","otherNames":[]},{"name":"melphalan","otherNames":[]},{"name":"autologous hematopoietic stem cell transplantation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary systemic amyloidosis\n\n  * Amyloid light-chain (AL) disease\n* Monoclonal protein by immunoelectrophoresis or immunofixation of the serum or urine OR abnormal free light-chain ratio\n* The following amyloid syndromes\\* are allowed:\n\n  * Amyloid hepatomegaly\n  * Cardiomyopathy\n  * Proteinuria\n  * Peripheral or autonomic neuropathy\n  * Soft tissue involvement including the tongue, submandibular tissues, and vascular claudication\n  * Diffuse interstitial pulmonary AL disease allowed if pulmonary function is adequate to allow safe transplantation NOTE: \\*Presence of amyloid deposits in a plasmacytoma or in bone marrow vessels in an asymptomatic patient does not constitute an amyloid syndrome\n* No secondary or familial amyloidosis\n* No multiple myeloma with lytic or destructive bone lesions or myeloma cast nephropathy\n* No multiple myeloma with \\> 30% plasma cells in the bone marrow\n* No amyloidosis manifested only by carpal tunnel syndrome or purpura\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Platelet count ≥ 100,000/mm³\n* Bilirubin ≤ 2.0 times upper limit of normal (ULN)\n* Alkaline phosphatase ≤ 6 times ULN\n* Creatinine ≤ 3.0 mg/dL\n* No NYHA class IV heart disease\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No uncontrolled infection\n* No HIV positivity\n\nPRIOR CONCURRENT THERAPY:\n\n* Prior alkylating agents, immunosuppressive drugs, or steroids allowed provided they were given for \\< 1 month\n\n  * Therapeutic steroid doses of ≤ 15 mg per day (or equivalent) allowed at discretion of physician\n* No concurrent participation in another clinical trial involving a pharmacologic agent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hematologic Response Rate","description":"Response that was confirmed on 2 consecutive evaluations during treatment. A hematologic response consisted of a Complete response, Very Good Partial Response or Partial Response.\n\n* Complete Response (CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and \\<5% plasma cells in bone marrow.\n* Very Good Partial Response (VGPR): \\>=90% reduction in serum M-component; Urine M-Component \\<=100 mg per 24 hours.\n* Partial Response (PR): \\>=50% reduction in serum M-component and/or Urine M-Component \\>=90% reduction or \\<200 mg per 24 hours; or \\>=50% decrease in difference between involved and uninvolved FLC levels.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":null},{"groupId":"OG001","value":"69.1","spread":null}]}]}]},{"type":"SECONDARY","title":"3 Year Overall Survival","description":"Percentage of patients who were alive at 3 years. The 3-year survival rate was estimated using the Kaplan Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8","spread":null},{"groupId":"OG001","value":"83.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Organ Response to Treatment","description":"Organ response was evaluated on the basis of improvement of one or more affected organ; only one parameter was required to satisfy the criteria. Response needed to be maintained for a minimum of 3 months to be considered valid.\n\nRenal response required a 50% reduction in 24-hour urine protein excretion (at least 0.5 g/d) with stable creatinine. Cardiac response required one of \\>= 2-mm reduction in the interventricular septal (IVS) thickness by echocardiogram, or improvement of ejection fraction by \\>= 20%, or improvement by 2 NYHA classes without an increase in diuretic use. Hepatic response required either \\>= 50% decrease in (or normalization of) an initially elevated alkaline phosphatase level or reduction in the size of the liver by at least 2 cm by radiographic determination. Gastrointestinal tract improvement was defined as normalization of a low serum carotene level, or reduction of diarrhea to \\< 50% of previous movements/day, or decrease in fecal fat excretion by 50%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"29.1","spread":null}]}]}]},{"type":"POST_HOC","title":"3-Year Progression Free Survival","description":"Percentage of patients who were progression free at 3 years. The 3-year progression free rate was estimated using the Kaplan Meier method.\n\nProgression is assessed when one of the following occur:\n\n* reappearance of monoclonal protein by immunofixation,\n* Increase in serum monoclonal paraprotein to \\>25% above the lowest response level,\n* Increase in urine M-protein to \\> 25% above the lowest remission value for 24-hour excretion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1","spread":null},{"groupId":"OG001","value":"51.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":34},"commonTop":["Fatigue","Edema limbs","Hemoglobin decreased","Platelet count decreased","Leukocyte count decreased"]}}}